Feel free to paste the table above directly into the bug, add any extra logs you have, and assign the appropriate owners.
RBD‑638’s delivers drug directly to the site of infection (airways), potentially shortening the therapeutic window and reducing systemic exposure compared with mAbs or oral antivirals.
Prepared 10 April 2026
| Trial | Population | Design | Primary Endpoint | Status | |-------|------------|--------|-------------------|--------| | (Phase II) | Adults 18‑65 y, ≤ 5 days from symptom onset, mild–moderate COVID‑19, unvaccinated or vaccine‑breakthrough | Randomised 1:1 (IV 1 mg/kg vs placebo) + standard of care | Time to sustained viral clearance (PCR < Ct 30 for ≥ 48 h) | Enrollment 70 % complete; interim analysis shows median clearance 2 days vs 5 days (p < 0.001). | | NCT05932178 (Phase III prophylaxis) | High‑risk healthcare workers, immunocompromised patients | Double‑blind, three‑arm (inhaled 4 mg weekly, IV 1 mg/kg every 10 days, placebo) | Incidence of laboratory‑confirmed COVID‑19 over 6 months | Ongoing; DSMB recommends continuation. | | NCT06001455 (Pediatric) | Ages 5‑17, post‑exposure prophylaxis | Open‑label, dose‑escalation inhaled | Safety & tolerability | Recruiting. |
RBD-638 uses an AAV vector to deliver a functional copy of the SMN1 gene to patients' cells, specifically to motor neurons. This allows the cells to produce a healthy copy of the SMN protein, reversing the effects of the SMN1 mutation and promoting motor neuron survival and function. The AAV vector is designed to be safe and efficient, allowing for the long-term expression of the SMN1 gene in treated cells. rbd-638
in poolB :
The potential benefits of RBD-638 are numerous: Feel free to paste the table above directly
– A C18‑PEG‑2000 tail attached at the C‑terminus enables albumin hitch‑hiking and lung surfactant interaction for inhaled delivery.
We have reproduced RBD‑638 consistently on a test environment (Octopus 15.2.7). The failure occurs only when the destination image lives on a remote pool (accessed via CephFS or a separate cluster). `rbd info` works, but `rbd export‑diff` aborts with “No such file or directory”. | | NCT05932178 (Phase III prophylaxis) | High‑risk
Key points: